Omid Akbari, PhD

Professor of Immunology and Immune Therapeutics and Medicine

Image of Omid Akbari, PhD
Is this your profile? Click to edit

Overview

We are cellular and molecular immunologists dedicated to advancing the understanding of the immune system. Our laboratory focuses on characterizing both innate and acquired immune responses, uncovering the mechanisms that regulate them, and investigating how they contribute to inflammatory diseases. We manipulate cell signaling pathways, costimulatory molecules, and cellular energy sources to modulate immune function and improve human health. Ultimately, our goal is to identify precise strategies to harness and control these responses for therapeutic benefit.

Awards

  • USC: Omid Akbari, 2025
     – 2030
  • Stanford University: American Lung Association award, 2001
     – 2003
  • Stanford University and Harvard Medical School: American Lung Association Grant Award, 2003
     – 2005
  • Stanford University: Pharmacia Research Foundation Award for the best research in the field of Immunology, Stockholm, 2003
  • Stanford University: Pharmacia Research Foundation Award for the best research in the field of Immunology, Amsterdam, 2004
  • Harvard Medical School: Pharmacia Research Foundation Award for the best research in the field of Immunology, Munich, 2005
  • Harvard Medical School: Henning Lowenstein Award for the best research in the field of Allergy and Immunology, Munich, 2005
  • Harvard Medical School: Eleanor & Miles Shore Career Development Award, 2007
     – 2008
  • Harvard Medical School: Children’s Hospital of Boston Career Development Award, 2007
     – 2008
  • University of Southern California: Ideas Empowered Award, 2012
     – 2013
  • University of Southern California: National Academy of Inventors Award, 2017
     – 2018
  • University of Southern California: Keck School of Medicine Dean’s award for scholarship, 2023

Research Funding

  • Mechanisms of Perinatal Nicotine Vaping-Induced Pulmonary ILC2 Dysregulation and Allergic Asthma Development
    NIH · R01HL183124 · Sep 1, 2026 – May 31, 2030 · Role: Co-Principal Investigator
  • Study the role of ICOS on murine and human ILC2s
    NIH · R01AI181866 · Jun 11, 2025 – May 31, 2030 · Role: Principal Investigator
  • Transcriptional and metabolomic regulation of IL-10 in pulmonary ILC2s
    NIH · R01AI169687 · Sep 20, 2022 – Jul 31, 2027 · Role: Principal Investigator
  • Role of TNF receptor 2 on Pulmonary Group 2 Innate Lymphoid Cells
    NIH · R01HL159804 · Dec 15, 2021 – Nov 30, 2025 · Role: Principal Investigator
  • Study the link of autophagy dysfunction to allergic and neutrophilic asthma onset
    NIH · R01HL151493 · Jul 1, 2020 – Jun 30, 2025 · Role: Principal Investigator
  • Induction of cells and pathways that promote respiratory tolerance in allergic asthma
    NIH · R01HL144790 · Sep 1, 2019 – Aug 31, 2023 · Role: Principal Investigator
  • Maternal effect on offspring immunity against hepatitis B virus
    NIH · R01AI145813 · Jul 3, 2019 – Jun 30, 2025 · Role: Co-Principal Investigator
  • Role of Microbiome Sodium Butyrate in regulation of ILC2 dependent airway hyperreactivity
    NIH · R21AI132084 · May 18, 2017 – Apr 30, 2020 · Role: Principal Investigator
  • The function of CRAC channels in airway inflammation
    NIH · R21AI109059 · Jan 1, 2016 – Dec 31, 2017 · Role: Co-Principal Investigator
  • Genetic and Environmental Determinants of Asthma Endophenotypes
    NIH · R01ES025786 · Aug 1, 2015 – Apr 30, 2021 · Role: Co-Principal Investigator
  • Air pollution, immune modulation of adipose tissue and type-2 diabetes risk factors
    NIH · R21ES024707 · Jul 10, 2014 – Jun 30, 2018 · Role: Co-Principal Investigator
  • INTEGRATIVE GENETIC APPROACHES TO GENE-AIR POLLUTION INTERACTIONS IN ASTHMA
    NIH · R01ES021801 · Aug 1, 2012 – Oct 31, 2019 · Role: Co-Principal Investigator
  • Role of NKT cells in airway hyperreactivity &tolerance
    NIH · R01AI066020 · Sep 20, 2007 – Aug 31, 2014 · Role: Principal Investigator

Publications

  • Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering. Front Immunol. 2026; 17:1844632.. View in PubMed
  • Autophagy as a Redox Rheostat Linking Cigarette Smoke, Electronic Cigarettes, and Nicotine Exposure to Lung Development, Disease, and Interorgan Communication. Compr Physiol. 2026 Jun; 16(3):e70167.. View in PubMed
  • Melatonin suppresses ILC2-driven airway hyperreactivity via glutathione-dependent metabolic reprogramming. Front Immunol. 2026; 17:1845654.. View in PubMed
  • Beyond ATP: Lipid-Driven Plasticity and the Immunometabolism of ILC2s. Cells. 2026 May 03; 15(9).. View in PubMed
  • Tim-3 agonist restrains ILC2 function and attenuates airway hyperreactivity via NLK pathway. Nat Commun. 2026 Apr 01; 17(1).. View in PubMed
  • Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance. Front Med (Lausanne). 2026; 13:1805170.. View in PubMed
  • Enhanced HIF-1α cooperation by a human RORγt mutant potentiates Th17 pathogenicity. Cell Rep. 2026 Mar 17; 45(4):117123.. View in PubMed
  • Targeting CD48 Ameliorates ILC2-mediated Airway Hyperreactivity by Disrupting the PKCβ Pathway. Am J Respir Cell Mol Biol. 2026 01 01; 74(1):65-79.. View in PubMed
  • The Expanding Role of ILC2s in Allergic Airways Disease. Allergy. 2026 01; 81(1):11-23.. View in PubMed
  • HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages. J Immunother Cancer. 2025 Aug 19; 13(8).. View in PubMed